Clinical Outcomes of 130 Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Treated with Palbociclib plus Endocrine Therapy and Subsequent Therapy: A Real-World Single-Center Retrospective Study in China

Documenti analoghi

• Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer
  di: Gelmon, Karen A., et al.
  Pubblicazione: (2019)
• A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
  di: Zhao, Yannan, et al.
  Pubblicazione: (2017)
• Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
  di: Masuda, Norikazu, et al.
  Pubblicazione: (2020)
• Clinical Prognosis and Nomograms for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Patients Treated with Palbociclib and Endocrine Therapy
  di: Song S, et al.
  Pubblicazione: (2025-07-01)
• Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
  di: Lin, Mingxi, et al.
  Pubblicazione: (2020)